Engelhard Corporation

Engelhard Minerals & Chemicals Corporation

Englehard Corporation

Alan R Amundsen

Eric W Stern

James D Hoeschele

Ronald Marshall Heck

Zhicheng Hu

Rudolf M Smaling

James D Hoeschel

An exhaust gas treatment apparatus and method for its use includes an upstream catalyst and a downstream catalyst. The upstream catalyst contains a catalytic metal effective at least for the oxidation of hydrocarbons in the exhaust gas stream, and preferably contains a palladium catalytic component and contains substantially no oxygen storage components, i.e., oxides of cerium, cobalt, iron, magnesium, molybdenum, nickel, praseodymium, tungsten and vanadium, but the downstream catalyst includes an oxygen storage component. Preferably, the upstream catalyst is a close-coupled catalyst. The downstream catalyst may be an underfloor catalyst or a close-coupled catalyst, in which case there is, preferably, an additional, underfloor catalyst.

Engine exhaust treatment apparatus and method of use

There is described a novel class of aminegold(III) complexes in which the nitrogen-containing ligand is an alkylamine, an arylamine or a heterocyclic amine. Said complexes are useful in the treatment of tumors in mammals.

Trihalo(amine)gold(III) anti-tumor complexes

There are described ionic bis(dicarboxylato)palladate(II) products derived from aliphatic and aromatic dicarboxylic acids useful in the treatment of malignant animal tumors sensitive thereto. Certain of the compounds are novel.

Ionic bis (Dicarboxylato) palladate (II)

There are described platinum-polyhydroxylated amine compounds which exhibit anti-tumor activity in mammalian species. The products are highly soluble in aqueous solutions and they may be administered either orally or in parenteral form.

Solubilized platinum (II) complexes

There are described novel bis(thiocyanato)palladium(II) complexes containing bidentate amine ligands. These complexes exhibit an anti-tumor effect against malignant animal tumor cells sensitive thereto and are characterized by low mammalian toxicity.

Bis(thiocyanato)palladium(II)complexes

There are described novel bis(thiocyanato)palladium(II) complexes containing bidentate amine ligands. These complexes exhibit an anti-tumor effect and are characterized by low mammalian toxicity.

Bis(thiocyanato)palladium(II) complexes

There are described ionic bis(dicarboxylato)palladate(II) products derived from aliphatic and aromatic dicarboxylic acids useful as anti-tumor agents in mammals. Certain of the compounds are novel.

Ionic bis(dicarboxylato)palladate(II) anti-tumor agents

A pharmaceutical composition having as the active ingredient a cis-platinum(II) amine lactate complex in which said amine is derived from ammonia or a monodentate or bidentrate amine ligand such as an alkylamine or alkylene diamine. Said compositions may be administered orally or parenterally and they exhibit pronounced activity against malignant animal tumor cells sensitive thereto.

Pharmaceutical composition containing cis-platinum (II) amine lactate

A pharmaceutical composition in which the active ingredient is an ascorbate complex of platinum (II) coordinated to ammonia, a monodentate amine ligand or a bidentate amine ligand as, for example, an alkylamine, an alkylenediamine or a cycloalkylamine. Said compositions are useful in the treatment of malignant tumors in animals. They may be administered orally or parenterally and they exhibit high solubility in water and low toxicity.

Method of using a cis-platinum(II) amine ascorbate

There are described ascorbate complexes of platinum(II) coordinated to ammonia, a monodentate amine ligand or a bidentate amine ligand as, for example, an alkylamine, an alkylenediamine or a cycloalkylamine. Said complexes are useful in the treatment of malignant tumors in animals and they are characterized by high solubility in water and low toxicity.

Cis-Platinum(II) amine ascorbate complexes

Cis-diammineplatinum (II) organophosphate complexes where the organophosphate moiety is a glycerophosphate or a monosaccharide phosphate moiety are prepared by reaction of cis-diaquodiammineplatinum (II) salts with alkali metal organophosphates. The resulting complexes possess pronounced anti-tumor activity and low toxicity; consequently, they have high therapeutic indices.

Method for treating tumors using cis-diammineplatinum (II)

Ethylenediamine platinum (II) and 1,2-diaminocyclohexane platinum (II) pyrophosphate complexes are prepared by reaction of the appropriate diaquo platinum (II) salt with a pyrophosphate salt. These complexes possess pronounced anti-tumor activity and low toxicity and thus have high therapeutic indices.

Method for treating tumors with ethylenediamine platinum (II) and

Cis-Platinum(II) amine lactate complexes are prepared by reaction of the appropriate platinum(II) amine chloride complex with silver lactate. These complexes possess pronounced anti-tumor activity and low toxicity and thus have high therapeutic indices. They are also highly soluble in water.

Cis-platinum (II) amine lactate complexes

Cis-diammineplatinum(II) orthophosphate complexes are prepared by reaction of diaquo-cis-diammineplatinum(II) salts with alkali metal orthophosphates. The resulting complexes possess pronounced anti-tumor activity in mice and low toxicity; consequently, they have high therapeutic indices.

Growing community of inventors

Somerville, NJ, United States of America

Alan R Amundsen